Literature DB >> 8656501

Serum HIV-1 RNA levels and time to development of AIDS in the Multicenter Hemophilia Cohort Study.

T R O'Brien1, W A Blattner, D Waters, E Eyster, M W Hilgartner, A R Cohen, N Luban, A Hatzakis, L M Aledort, P S Rosenberg, W J Miley, B L Kroner, J J Goedert.   

Abstract

OBJECTIVE: To determine if the long-term incidence of the acquired immunodeficiency syndrome (AIDS) is related to human immunodeficiency virus type 1 (HIV-1) RNA levels measured early in HIV-1 infection.
DESIGN: Epidemiologic cohort study.
SETTING: Five hemophilia treatment centers in the United States.
SUBJECTS: A total of 165 subjects with hemophilia and HIV-1 infection (age at HIV-1 seroconversion, 1-66 years) followed from 1979 to 1995.
METHODS: The HIV-1 RNA level was measured by polymerase chain reaction over a range of 200 to 1 million or more HIV-1 RNA copies/mL in archived serum specimens collected 12 to 36 months (median, 27 months) after the estimated date of HIV-1 seroconversion. Kaplan-Meier methods were used to examine the risk of AIDS and proportional hazards models were used to estimate relative hazards.
RESULTS: The HIV-1 RNA values were similar in subjects younger than 17 years at seroconversion (median, 5214 copies/mL) and those 18 to 34 years old (median, 4693 copies/mL), but higher in those 35 years or older (median, 12069 copies/mL) (P = .02 compared with each younger group). At 10 years after seroconversion, the proportions of subjects with AIDS were 72% among subjects with 100,000 or more HIV-1 RNA copies/mL measured 12 to 36 months after HIV-1 seroconversion (n = 9), 52% among subjects with 10,000 to 99,999 copies/mL (n = 55), 22% among subjects with 1000 to 9,999 copies/mL (n = 82), and 0% among subjects with fewer than 1000 copies/mL (n = 19) (P < .001). The age-adjusted relative hazard for AIDS for subjects with 10,000 or more copies/mL was 14.3 (95% confidence interval, 1.9-105.6) compared with subjects with fewer than 1000 copies/mL.
CONCLUSIONS: The HIV-1 RNA level during early chronic HIV-1 infection is a strong, age-independent predictor of clinical outcome; low levels define persons with a high probability of long-term AIDS-free survival.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8656501

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  63 in total

1.  A simple relationship between viral load and survival time in HIV-1 infection.

Authors:  R A Arnaout; A L Lloyd; T R O'Brien; J J Goedert; J M Leonard; M A Nowak
Journal:  Proc Natl Acad Sci U S A       Date:  1999-09-28       Impact factor: 11.205

2.  Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects.

Authors:  G M Ortiz; M Wellons; J Brancato; H T Vo; R L Zinn; D E Clarkson; K Van Loon; S Bonhoeffer; G D Miralles; D Montefiori; J A Bartlett; D F Nixon
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-30       Impact factor: 11.205

3.  Principles of quantitation of viral loads using nucleic acid sequence-based amplification in combination with homogeneous detection using molecular beacons.

Authors:  Jos J A M Weusten; Wim M Carpay; Tom A M Oosterlaken; Martien C A van Zuijlen; Paul A van de Wiel
Journal:  Nucleic Acids Res       Date:  2002-03-15       Impact factor: 16.971

4.  Live, attenuated simian immunodeficiency virus vaccines elicit potent resistance against a challenge with a human immunodeficiency virus type 1 chimeric virus.

Authors:  R Shibata; C Siemon; S C Czajak; R C Desrosiers; M A Martin
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

5.  Viral dynamics of primary viremia and antiretroviral therapy in simian immunodeficiency virus infection.

Authors:  M A Nowak; A L Lloyd; G M Vasquez; T A Wiltrout; L M Wahl; N Bischofberger; J Williams; A Kinter; A S Fauci; V M Hirsch; J D Lifson
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

6.  Impact of the COBAS AmpliPrep/COBAS AMPLICOR HIV-1 MONITOR Test, Version 1.5, on clinical laboratory operations.

Authors:  Jeffrey J Germer; Jordan L Bendel; Craig A Dolenc; Sarah R Nelson; Amanda L Masters; Tara M Gerads; Jayawant N Mandrekar; P Shawn Mitchell; Joseph D C Yao
Journal:  J Clin Microbiol       Date:  2007-07-18       Impact factor: 5.948

7.  High levels of viral replication contrast with only transient changes in CD4(+) and CD8(+) cell numbers during the early phase of experimental infection with simian immunodeficiency virus SIVmnd-1 in Mandrillus sphinx.

Authors:  Richard Onanga; Christopher Kornfeld; Ivona Pandrea; Jerome Estaquier; Sandrine Souquière; Pierre Rouquet; Virginie Poaty Mavoungou; Olivier Bourry; Souleymane M'Boup; Françoise Barré-Sinoussi; François Simon; Cristian Apetrei; Pierre Roques; Michaela C Müller-Trutwin
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

8.  Quantitation of human immunodeficiency virus type 1 DNA forms with the second template switch in peripheral blood cells predicts disease progression independently of plasma RNA load.

Authors:  Leondios G Kostrikis; Giota Touloumi; Rose Karanicolas; Nikos Pantazis; Cleo Anastassopoulou; Anastasia Karafoulidou; James J Goedert; Angelos Hatzakis
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

9.  Viral load and CD4+ T-cell dynamics in primary HIV-1 subtype C infection.

Authors:  Vladimir Novitsky; Elias Woldegabriel; Lemme Kebaabetswe; Raabya Rossenkhan; Busisiwe Mlotshwa; Caitlin Bonney; Mariel Finucane; Rosemary Musonda; Sikhulile Moyo; Carolyn Wester; Erik van Widenfelt; Joseph Makhema; Stephen Lagakos; M Essex
Journal:  J Acquir Immune Defic Syndr       Date:  2009-01-01       Impact factor: 3.731

Review 10.  The potential role of biomarkers in HIV preventive vaccine trials.

Authors:  Ellen Maclachlan; Kenneth H Mayer; Ruanne Barnabas; Jorge Sanchez; Beryl Koblin; Ann Duerr
Journal:  J Acquir Immune Defic Syndr       Date:  2009-08-15       Impact factor: 3.731

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.